HBC-00015875

HBC-00015875 is a potent and selective small molecule inhibitor of Werner Syndrome Helicase (WRN), a member of the RecQ family of helicases essential for maintaining genomic stability. Developed by Hansoh Bio, the compound is designed to exploit synthetic lethality in microsatellite instability-high (MSI-H) cancer cells, which are deficient in the DNA mismatch repair (MMR) system. Preclinical evaluations in colorectal, endometrial, and gastric cancer models have shown that HBC-00015875 exhibits favorable pharmacokinetic properties and induces significant tumor growth inhibition. Its efficacy is closely associated with the induction of pharmacodynamic biomarkers and the degradation of the WRN protein, supporting its potential as a targeted therapy for patients with MSI-H malignancies who may not respond to standard immune checkpoint inhibitors.